Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation

Bone Marrow Transplant. 2015 Mar;50(3):455-6. doi: 10.1038/bmt.2014.272. Epub 2014 Dec 8.

Authors

G M T Guilcher¹, R Moorjani¹, T H Truong¹, V A Lewis¹

Affiliation

¹ University of Calgary, Section of Haematology/Oncology/Transplant, Alberta Children's Hospital, Calgary, Canada.

PMID: 25486583
DOI: 10.1038/bmt.2014.272

No abstract available

Publication types

Letter

MeSH terms

Antilymphocyte Serum / administration & dosage*
Busulfan / administration & dosage*
Child, Preschool
Combined Modality Therapy
Hematopoietic Stem Cell Transplantation / methods*
Humans
Infant
Leukemia, Myelomonocytic, Juvenile / drug therapy
Leukemia, Myelomonocytic, Juvenile / therapy*
Myeloablative Agonists / administration & dosage*
Transplantation Conditioning / methods*
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives*
Whole-Body Irradiation / methods*

Substances

Antilymphocyte Serum
Myeloablative Agonists
Vidarabine
Busulfan
fludarabine